Dr. James Markowitz, MD
Pediatric Gastroenterology (Pediatric Gastroenterology Physician)
Sch - Pediatric Gastroenterology, 269-01 76th Avenue
New Hyde Park, NY 11040
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Gastroenterology Physician primary
NY license 134754
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 1 companies reported 11 payments worth $12,160 in total to this clinician.
| Janssen Scientific Affairs, LLC | $12,160 |
|---|
| Consulting Fee | $10,500 |
|---|---|
| Travel and Lodging | $1,265 |
| Food and Beverage | $395 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Scientific Affairs, LLC Feb 24, 2025 | Consulting Fee REMICADE · Immunology | $9,000 |
| Janssen Scientific Affairs, LLC Aug 14, 2025 | Consulting Fee REMICADE · Immunology | $1,500 |
| Janssen Scientific Affairs, LLC Jan 11, 2025 | Travel and Lodging REMICADE · Immunology · travel to PHILADELPHIA, PA · in-kind | $802 |
| Janssen Scientific Affairs, LLC Jan 11, 2025 | Travel and Lodging REMICADE · Immunology · travel to PHILADELPHIA, PA · in-kind | $463 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $29,914 in research payments for these studies, mostly to the institutions running them.
- Openlabel induction and maintenance study of oral CP690550 tofacitinib in children with moderately to severely active ulcerative colitis
Pfizer Inc. - A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
AbbVie Inc. · Active, not recruiting · NCT02130362 - A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease (DEVELOP)
Janssen Research & Development, LLC - A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn Disease (CD)
AbbVie Inc. - A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.